FDA Accepts Its First Biosimilar Application: However, the Agency’s Requirements Are Still Unclear

Documenti analoghi

• Conflicting Opinions Flood FDA on Its Proposal for Biosimilar Naming
  di: Barlas, Stephen
  Pubblicazione: (2016)
• FDA Advisory Committee Approval of First Biosimilar Leaves Questions Unanswered: Sandoz’s Filgrastim Faces Naming and Court Hurdles
  di: Barlas, Stephen
  Pubblicazione: (2015)
• FDA Pleases No One With Final Guidance On Naming of Biologicals and Biosimilars
  di: Barlas, Stephen
  Pubblicazione: (2017)
• Early Biosimilars Face Hurdles to Acceptance: The FDA Has Approved Few, So Lack of Competition Is Keeping Prices High
  di: Barlas, Stephen
  Pubblicazione: (2016)
• Under Scrutiny: FDA’s REMS for Opioids: Acceptance or Rejection by Stakeholders Will Influence Congress
  di: Barlas, Stephen
  Pubblicazione: (2012)